Long-term outcomes of sacral neuromodulation for anorectal disorders: a retrospective single- center cohort study
This retrospective single-center cohort study demonstrates that sacral neuromodulation provides sustained long-term treatment success for fecal incontinence over a median follow-up of 7.6 years, while highlighting the need for larger studies to better define outcomes for low anterior resection syndrome and refractory constipation due to limited sample sizes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For many people, the body's ability to control when and how they release waste is a quiet, automatic function that rarely enters conscious thought. When this system fails, however, it becomes a source of profound distress, forcing individuals to alter their daily lives, avoid social gatherings, and live in constant fear of an accident. This condition, known as fecal incontinence, is not merely a minor inconvenience but a disabling state that can lead to severe isolation and depression. While the exact mechanisms of why the body loses this control vary, the goal of treatment is often to restore the strength and sensitivity of the muscles and nerves that act as a gatekeeper for the rectum. For decades, surgeons have turned to a technique called sacral neuromodulation, which involves placing a small device near the lower spine to send gentle electrical pulses to the nerves that control the bowel. Think of this device as a pacemaker for the bowel, gently reminding the nerves to function correctly. While this method has been well-studied for urinary issues and is established for bowel control, doctors have been less certain about how well it holds up over many years, especially when used for other bowel problems like severe constipation or the difficult symptoms that can follow major rectal surgery.
A team of surgeons at the University Hospitals of Strasbourg in France set out to answer these questions by looking back at their own long-term experience with this procedure. They gathered data from ninety-five patients who had received these nerve stimulators between 2002 and 2026. The vast majority of these patients were women, and most were being treated for fecal incontinence, though a smaller number were treated for severe constipation or the aftermath of a surgery known as a low anterior resection. The researchers followed these patients for a median of seven and a half years, a significant stretch of time that allowed them to see not just if the treatment worked initially, but if it continued to work as the years passed. Their primary goal was to determine how many patients could keep using the device successfully without needing to have it removed because it stopped helping.
The results showed that for the majority of patients, the treatment provided lasting relief. Of the ninety-five people who started the process, ninety-one successfully moved from a temporary test phase to a permanent implant. Over the long term, seventy-one of these patients, or roughly three out of every four, were still successfully using the device at their last check-up. For those treated specifically for incontinence, the improvement was clear: the average score measuring the severity of their symptoms dropped significantly from a high level of severity at the start to a moderate level during follow-up. The researchers noted that the type of condition being treated mattered; patients with incontinence were more likely to have a successful long-term outcome compared to those treated for constipation or post-surgical bowel issues, though the numbers for these smaller groups were too low to draw firm conclusions about them.
However, the path to success was not without obstacles. The study found that nearly nineteen percent of the patients experienced complications that required medical attention. About half of these issues were infections at the site where the device was placed, while the other half involved mechanical problems, such as the wire moving out of place or a connector breaking. Because these complications often required surgery to fix or remove the device, they were considered significant. Despite these risks, the researchers observed that the treatment remained a viable option for a substantial number of people over many years. The study also highlighted that the definition of "failure" can be tricky; sometimes a device is removed not because it stopped working, but because the battery died and the patient did not get a replacement, or because the symptoms returned after an initial period of relief.
Ultimately, this long-term look at the data suggests that sacral neuromodulation is a durable solution for many people struggling with bowel control, particularly for those with incontinence. The surgeons emphasized that while the results are encouraging, the small number of patients treated for other conditions like constipation means that more research is needed to fully understand how the procedure works for those specific cases. They concluded that future studies should involve more patients and follow them with a consistent plan to better understand who benefits most and how to manage the inevitable wear and tear of the devices over time. For now, the data offers a clear picture: for a significant portion of patients, this technology provides a sustained way to regain control and improve their quality of life over the course of many years.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.